drugset / Trial / NCT01627106

A Study Comparing Vernakalant Therapy to Amiodarone Therapy in Acute Management of Recent Onset Atrial Fibrillation (AF) (MK-6621-055)

NCT01627106

Phase 4 Withdrawn Advanz Pharma
RandomizedParallel-groupOpen-labelTreatment

Summary

This study will compare vernakalant therapy to amiodarone therapy in the acute management of recent onset atrial fibrillation.

Timeline

Start
2012-09
Primary completion
2016-02
Completion
2016-03

Drugs

EvaluationDrugModalityDoseRoute
Comparator Amiodarone Small molecule Intravenous
Subject Vernakalant Other / unclassified 3 mg/kg Intravenous

Indications